Asset Details
Do you wish to reserve the book?
Should adjuvant chemotherapy become standard treatment in all patients with resected non-small-cell lung cancer?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Should adjuvant chemotherapy become standard treatment in all patients with resected non-small-cell lung cancer?
Do you wish to request the book?
Should adjuvant chemotherapy become standard treatment in all patients with resected non-small-cell lung cancer?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Should adjuvant chemotherapy become standard treatment in all patients with resected non-small-cell lung cancer?
2005
Overview
Surgery remains the main curative treatment for patients with early-stage non-small-cell lung cancer (NSCLC); however, because many patients probably have undetectable micrometastasis even at diagnosis, adjuvant treatment is usually needed. The results for radiotherapy have mostly been disappointing, and a strong emphasis has, therefore, been placed on chemotherapy as the preferred modality. Adjuvant chemotherapy, and in particular, platinum-based regimens, have been assessed in several studies, but the results have been conflicting. Most trials have included patients with a wide range of disease stages and have shown, at most, only moderate improvements in survival. Thus, although clearly indicated in some patients, whether adjuvant chemotherapy should be used in all patients with resected disease is highly controversial. In this debate, Thierry Le Chevalier and colleagues and Giorgio Scagliotti present opposing arguments for whether this approach should be considered standard.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
Antineoplastic Combined Chemotherapy Protocols
/ Carcinoma, Non-Small-Cell Lung - drug therapy
/ Carcinoma, Non-Small-Cell Lung - mortality
/ Carcinoma, Non-Small-Cell Lung - surgery
/ Disease
/ Humans
/ Lung Neoplasms - drug therapy
/ Non-small cell lung carcinoma
/ Oncology
/ Patients
/ Randomized Controlled Trials as Topic
/ Studies
/ Surgery
